PMID- 16947041
OWN - NLM
STAT- MEDLINE
DCOM- 20071019
LR  - 20181113
IS  - 0179-1958 (Print)
IS  - 0179-1958 (Linking)
VI  - 22
IP  - 5
DP  - 2007 May
TI  - HER-2/neu overexpression is an independent prognostic factor in colorectal 
      cancer.
PG  - 491-7
AB  - BACKGROUND AND AIMS: The HER-2/neu protein is intimately involved with normal 
      cell proliferation and tissue growth, as it is extensively homologous and is 
      related to the epidermal growth factor receptor. This phenomenon has been most 
      intensively studied in the context of breast carcinoma, in which its 
      amplification and overexpression correlate with the overall course of disease and 
      poor prognoses, and also constitute a predictive factor of poor response to 
      chemotherapy and endocrine therapy. In this study, we investigated the 
      relationships between the expression of HER-2/neu and the clinicopathological 
      characteristics of colorectal cancer, including survival. This study was 
      performed with a view toward the future introduction of Herceptin therapy for 
      colorectal cancer patients. PATIENTS AND METHODS: HER-2/neu overexpression and 
      gene amplification were examined via semiquantitative standardized 
      immunohistochemical staining and fluorescence in situ hybridization (FISH) in 137 
      colorectal cancer patients who underwent curative surgery at the Kangbuk Samsung 
      Hospital. RESULTS: Sixty-five (47.4%) out of 137 patients were determined by 
      immunohistochemistry to have overexpressed HER-2/neu protein. HER-2/neu gene 
      amplification was detected in two patients by FISH. Tumors with HER-2/neu 
      overexpression showed higher postoperative recurrence rate (39.3% vs 14.6%, 
      p=0.013). Tumors with HER-2/neu overexpression were associated with poor 3-year 
      (70.8% vs 83.7%) and 5-year survival rates (55.1% vs 78.3%, p<0.05). Advanced TNM 
      stage, postoperative recurrence, and overexpression of HER-2/neu were found to be 
      independently related to survival by multivariate analysis. CONCLUSION: HER-2/neu 
      overexpression may constitute an independent prognostic factor in colorectal 
      cancer patients, and patients exhibiting HER-2/neu overexpression might 
      constitute potential candidates for a new adjuvant therapy which involves the use 
      of humanized monoclonal antibodies.
FAU - Park, Dong Il
AU  - Park DI
AD  - Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School 
      of Medicine, Seoul, South Korea.
FAU - Kang, Mun Su
AU  - Kang MS
FAU - Oh, Suk Joong
AU  - Oh SJ
FAU - Kim, Hong Joo
AU  - Kim HJ
FAU - Cho, Yong Kyun
AU  - Cho YK
FAU - Sohn, Chong Il
AU  - Sohn CI
FAU - Jeon, Woo Kyu
AU  - Jeon WK
FAU - Kim, Byung Ik
AU  - Kim BI
FAU - Han, Won Kon
AU  - Han WK
FAU - Kim, Hungdai
AU  - Kim H
FAU - Ryu, Seung Ho
AU  - Ryu SH
FAU - Sepulveda, Antonia R
AU  - Sepulveda AR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060901
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*genetics/*mortality/pathology/surgery
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Profiling
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Korea/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Recurrence, Local/genetics
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Receptor, ErbB-2/*genetics
MH  - Survival Rate
EDAT- 2006/09/02 09:00
MHDA- 2007/10/20 09:00
CRDT- 2006/09/02 09:00
PHST- 2006/07/11 00:00 [accepted]
PHST- 2006/09/02 09:00 [pubmed]
PHST- 2007/10/20 09:00 [medline]
PHST- 2006/09/02 09:00 [entrez]
AID - 10.1007/s00384-006-0192-8 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2007 May;22(5):491-7. doi: 10.1007/s00384-006-0192-8. Epub 
      2006 Sep 1.